CredoScientia - Bibliothèque

Case Report: Successful Surgical Resection of PVTT Vp4 Hepatocellular Carcinoma Following Hepatic Arterial Infusion Chemotherapy Combined with Cadonilimab Plus Donafenib.

OBJECTIVE: To evaluate the potential and efficacy of hepatic artery infusion chemotherapy combined with the PD-1/CTLA-4 bispecific antibody cadonilimab and the multi-kinase inhibitor donafenib in conv…

Thérapies de Conversion

Chen, S., Wei, Y., Liao, X., Yang, C., Zhu, G., Han, C., Su, H., & Peng, T. (2025). Case Report: Successful Surgical Resection of PVTT Vp4 Hepatocellular Carcinoma Following Hepatic Arterial Infusion Chemotherapy Combined with Cadonilimab Plus Donafenib.. Pharmgenomics Pers Med, 18, 279-286. https://doi.org/10.2147/PGPM.S555061

01/01/2025 Lire →

Correction: Immunotherapy in conversion therapy for gastric cancer: current status, progress, and challenges.

[This corrects the article DOI: 10.3389/fonc.2025.1637657.].

Thérapies de Conversion

Su, Y., Zhang, X., & Deng, W. (2025). Correction: Immunotherapy in conversion therapy for gastric cancer: current status, progress, and challenges.. Front Oncol, 15, 1730862. https://doi.org/10.3389/fonc.2025.1730862

01/01/2025 Lire →

Chemotherapy alone versus chemotherapy plus targeted therapy as adjuvant therapy for initially unresectable colorectal cancer liver metastases: a multicenter cohort study.

BACKGROUND: There is no consensus on the adjuvant treatment regimen for patients with colorectal cancer liver metastasis (CRLM) who have achieved successful conversion after surgery. This study aimed …

Thérapies de Conversion

Chang, W., Zhou, S., Guan, X., Xu, D., Liu, Y., Tang, W., Lv, Y., Qin, X., Liang, F., Wang, X., Ren, L., Fan, J., Wei, Y., Wang, X., & Xu, J. (2025). Chemotherapy alone versus chemotherapy plus targeted therapy as adjuvant therapy for initially unresectable colorectal cancer liver metastases: a multicenter cohort study.. Gastroenterol Rep (Oxf), 13, goaf098. https://doi.org/10.1093/gastro/goaf098

01/01/2025 Lire →

Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.

BACKGROUND: Conversion therapy provides patients with intermediate-advanced hepatocellular carcinoma (HCC) an opportunity for radical resection, but the prognostic significance of residual tumor in re…

Thérapies de Conversion

Zhang, H., Yang, T., Huang, L., Li, B., Xu, H., & Wei, Y. (2025). Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.. Front Immunol, 16, 1704239. https://doi.org/10.3389/fimmu.2025.1704239

01/01/2025 Lire →

Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis.

BACKGROUND: Due to its rarity, synchronous double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma (sdpHCC-ICC) presents significant challenges for preoperative diagnosis and is la…

Thérapies de Conversion

He, Y. C., Dai, X. Y., Lv, Y. H., Yang, X. J., Xie, Q. Y., Xie, S. N., Cai, Y. S., Gao, F. W., & Lan, T. (2025). Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis.. Front Oncol, 15, 1670818. https://doi.org/10.3389/fonc.2025.1670818

01/01/2025 Lire →

Spontaneous Rupture of Hepatocellular Carcinoma: Pathogenesis, Clinical Management, Prognostic Factors, and Future Directions.

Spontaneous rupture of hepatocellular carcinoma (srHCC) is a life-threatening complication with complex pathophysiology and heterogeneous clinical presentations. This review aims to provide an up-to-d…

Thérapies de Conversion

Cheng, Y., Ye, F., & Chen, Y. (2025). Spontaneous Rupture of Hepatocellular Carcinoma: Pathogenesis, Clinical Management, Prognostic Factors, and Future Directions.. J Hepatocell Carcinoma, 12, 2421-2428. https://doi.org/10.2147/JHC.S540510

01/01/2025 Lire →

Pathological complete response to conversion therapy for lung adenocarcinoma with brain metastasis: a case report.

Lung cancer is the leading cause of cancer mortality worldwide. Fortunately, the advent of precision medicine, which includes targeted therapy and immunotherapy, has significantly improved the surviva…

Thérapies de Conversion

Ran, X., Luo, T., Xiong, J., & Fu, M. (2025). Pathological complete response to conversion therapy for lung adenocarcinoma with brain metastasis: a case report.. Front Oncol, 15, 1625918. https://doi.org/10.3389/fonc.2025.1625918

01/01/2025 Lire →

Case Report: Efficacy of preoperative conversion therapy with lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy in an advanced hepatocellular carcinoma.

Advanced hepatocellular carcinoma (HCC) has a poor prognosis. Conversion therapy based on non-surgical local therapy and drug therapy is an effective treatment for unresectable HCC. We report a case o…

Thérapies de Conversion

Mao, J., Zhang, H., Yang, X., Yao, Y., Sun, X., & Yan, Q. (2025). Case Report: Efficacy of preoperative conversion therapy with lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy in an advanced hepatocellular carcinoma.. Front Oncol, 15, 1627281. https://doi.org/10.3389/fonc.2025.1627281

01/01/2025 Lire →

Pathologic complete response of advanced hepatoid adenocarcinoma of the stomach following immuno-chemotherapy and conversion surgery: a rare case report and review of the literature.

BACKGROUND: Hepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer (GC) characterized by alpha-fetoprotein (AFP) production and invasive liver and lymph node metastases, typi…

Thérapies de Conversion

Li, Y., Wang, Y., Yu, T., Wang, D., Ma, H., Ma, J., & Da, M. (2025). Pathologic complete response of advanced hepatoid adenocarcinoma of the stomach following immuno-chemotherapy and conversion surgery: a rare case report and review of the literature.. Front Oncol, 15, 1648766. https://doi.org/10.3389/fonc.2025.1648766

01/01/2025 Lire →

Immunotherapy in conversion therapy for gastric cancer: current status, progress, and challenges.

Gastric cancer remains a global health burden due to its late diagnosis and poor prognosis. Conversion therapy aims to make the initially unresectable tumor resectable through systemic treatment, prov…

Thérapies de Conversion

Su, Y., Zhang, X., & Deng, W. (2025). Immunotherapy in conversion therapy for gastric cancer: current status, progress, and challenges.. Front Oncol, 15, 1637657. https://doi.org/10.3389/fonc.2025.1637657

01/01/2025 Lire →

TPF regimen improves conversion surgery and short-term survival in patients with locally unresectable advanced gastric cancer.

OBJECTIVE: To compare the efficacy and safety of TPF versus FOLFOX regimens in conversion therapy for locally unresectable advanced gastric cancer (LAUGC) and to identify prognostic factors influencin…

Thérapies de Conversion

Duan, T., Ma, D., Bai, Z., Ding, X., & Zhang, X. (2025). TPF regimen improves conversion surgery and short-term survival in patients with locally unresectable advanced gastric cancer.. Am J Transl Res, 17(8), 6068-6079. https://doi.org/10.62347/FFQN8329

01/01/2025 Lire →

Development and validation of a prognostic nomogram for unresectable pancreatic ductal adenocarcinoma with synchronous liver metastases: a study based on the SEER database and an external cohort.

BACKGROUND: Pancreatic ductal adenocarcinoma with synchronous liver metastases (PDACLM) represents a highly aggressive malignancy with limited treatment options and poor prognosis. While conversion th…

Thérapies de Conversion

Huan, L., He, Q., Cao, Y., Liu, C., & Li, Y. (2025). Development and validation of a prognostic nomogram for unresectable pancreatic ductal adenocarcinoma with synchronous liver metastases: a study based on the SEER database and an external cohort.. Front Oncol, 15, 1636715. https://doi.org/10.3389/fonc.2025.1636715

01/01/2025 Lire →